Cargando…
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
There are limited data for the clinical efficacy of bebtelovimab in preventing severe coronavirus disease 2019. Among outpatients unable to take nirmatrelvir-ritonavir at a large health system, 10 of 377 (2.7%) patients who received bebtelovimab and 17 of 377 (4.5%) matched untreated patients were h...
Autores principales: | Dryden-Peterson, Scott, Kim, Andy, Joyce, Mary-Ruth, Johnson, Jennifer A, Kim, Arthur Y, Baden, Lindsey R, Woolley, Ann E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620388/ https://www.ncbi.nlm.nih.gov/pubmed/36438619 http://dx.doi.org/10.1093/ofid/ofac565 |
Ejemplares similares
-
Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system
por: Dryden-Peterson, Scott, et al.
Publicado: (2022) -
Bebtelovimab-Induced Bradycardia Leading to Cardiac Arrest
por: Gearges, Christina, et al.
Publicado: (2022) -
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic
por: Nichols, Russell M, et al.
Publicado: (2022) -
The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis
por: Luo, Jie, et al.
Publicado: (2023) -
Outcomes of Bebtelovimab Therapy in Patients With Solid Organ Transplantation With Mild and Moderate COVID-19
por: Kapur, Rohan, et al.
Publicado: (2023)